Patents by Inventor Willem J.M. Mulder

Willem J.M. Mulder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • APOLIPOPROTEIN FUSION PROTEINS FOR CELL-SPECIFIC IMMUNE REGULATION
    Publication number: 20240391978
    Abstract: The invention relates to fusion proteins of apolipoprotein with an immunomodulatory biomolecule and/or a rerouting molecule. The fusion proteins can be used as a carrier for an immunomodulatory biomolecule as such or incorporated in a lipid nanoparticle. The fusion protein finds use in the treatment of immune related disorders, or targeting a payload to a specific target site.
    Type: Application
    Filed: September 23, 2022
    Publication date: November 28, 2024
    Inventors: Roy VAN DER MEEL, Willem J.M. MULDER, Maarten MERKX, David Pepijn SCHRIJVER, Anne DE DREU, Ayla Martine HOKKE, Koen DE BRUIN
  • Nucleic Acid Containing Nanoparticles
    Publication number: 20240216291
    Abstract: Herein disclosed are nanoparticles comprising a phospholipid, apolipoprotein and/or an apolipoprotein mimetic, sterol, cationic lipid or ionizable cationic lipid and a nucleic acid and compositions comprising such nanoparticles and a method for preparing such nanoparticles. The nanoparticles may be used as a medicament, such as in the treatment of a disease by stimulating or inhibiting an innate immune response.
    Type: Application
    Filed: June 22, 2022
    Publication date: July 4, 2024
    Inventors: Roy VAN DER MEEL, Willem J.M. MULDER, Ewelina KLUZA, Stijn HOFSTRAAT, Tom ANBERGEN, Robby Cornelis ZWOLSMAN, Henricus Marie JANSSEN, Pieter Michele FRANSEN
  • COMPOUNDS FOR REGULATING TRAINED IMMUNITY, AND THEIR METHODS OF USE
    Publication number: 20240190921
    Abstract: Provided herein are compounds of Formula (I), as well as compositions comprising a compound of Formula (I) and uses thereof.
    Type: Application
    Filed: November 15, 2023
    Publication date: June 13, 2024
    Inventors: Henricus Marie Janssen, Freek Johannes Maria Hoeben, Bas Van Genabeek, Serge Hendrikus Mathijs Sontjens, Willem J. M. Mulder
  • Compounds for regulating trained immunity, and their methods of use
    Patent number: 11859021
    Abstract: Provided herein are compounds of Formula (I), as well as compositions comprising a compound of Formula (I) and uses thereof.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: January 2, 2024
    Assignees: Icahn School of Medicine at Mount Sinai, Trained Therapeutix Discovery, Inc.
    Inventors: Henricus Marie Janssen, Freek Johannes Maria Hoeben, Bas Van Genabeek, Serge Hendrikus Mathijs Sontjens, Willem J. M. Mulder
  • COMPOUNDS FOR REGULATING TRAINED IMMUNITY, AND THEIR METHODS OF USE
    Publication number: 20220332762
    Abstract: Provided herein are compounds of Formula (I), as well as compositions comprising a compound of Formula (I) and uses thereof.
    Type: Application
    Filed: March 18, 2022
    Publication date: October 20, 2022
    Inventors: Henricus Marie JANSSEN, Freek Johannes Maria HOEBEN, Bas VAN GENABEEK, Serge Hendrikus Mathijs SONTJENS, Willem J. M. MULDER
  • BIMODAL FLUOROPHORE-LABELED LIPOSOMES AND ASSOCIATED METHODS AND SYSTEMS
    Publication number: 20150343100
    Abstract: Described herein is a non-invasive quantitative positron emission tomography (PET) nanoreporter technology that allows personalized therapeutic outcome prediction. In a breast cancer mouse model, it was demonstrated that co-injecting Doxil and a Zirconium-89 nanoreporter (89Zr-NRep) enabled highly precise doxorubicin (DOX) quantification. Imaging 89Zr-NRep via PET revealed remarkable Doxil accumulation heterogeneity independent of tumor size.
    Type: Application
    Filed: May 27, 2015
    Publication date: December 3, 2015
    Inventors: Carlos Perez-Medina, Thomas Reiner, Jason S. Lewis, Willem J.M. Mulder, Zahi A. Fayad